[Ms. Cecilia Gonzalo has been appointed as Director of Talon Therapeutics, Inc. She is a Managing Director at Warburg Pincus LLC and a General Partner of Warburg Pincus & Co., where she focuses on healthcare investments in the biotechnology, pharmaceuticals, and healthcare services sectors. Prior to joining Warburg Pincus in 2001, Ms. Gonzalo worked at Goldman Sachs in the firm’s Investment Banking Division focusing on corporate finance and mergers and acquisitions transactions in Latin America, as well as in the Principal Investment Area focusing on investments in the region. Ms. Gonzalo received a B.A., cum laude, in Biochemical Sciences from Harvard College and an M.B.A. from Harvard Business School. Ms. Gonzalo also serves as a director of Allos Therapeutics and Rib-X Pharmaceuticals.]
I believe tech's post is a cut and paste of a Bio of the BOD from the TLON web site. Ms Gonzalo has the skills to make a buyout happen, She is one of three from WP on the BOD. Selling of companys is how WP earns their money. They are the primary owners of TLON.
WP is the primary investor (stakeholder) and she works for them. WP will make their money when the liquidate their position by selling the company, that is what they do. Ms. Gonzalo is one of three WP members on the BOD, her skills will help to facilitate selling TLON.